46662-2020 - Išankstinis skelbimas apie tiesioginį sutarties skyrimą

See the notice on TED website

Jungtinė Karalystė, Didžioji Britanija-Bristolis: Patologijų gydymo paslaugos
OJ S 21/2020 30/01/2020
Savanoriškas išankstinis skaidrumo skelbimas
Paslaugos

Teisinis pagrindas:
Direktyva 2014/24/ES

I dalis: Perkančioji organizacija ar perkantysis subjektas

I.1. Pavadinimas ir adresai

Oficialus pavadinimas: North Bristol NHS Trust
Adresas: Southmead Road, Bristol
Miestas: Bristol
NUTS kodas: UKK11 Bristol, City of
Pašto kodas: BS10 5NB
Šalis: Jungtinė Karalystė
Asmuo ryšiams: Martin Strawson
El. paštas: martin.strawson@UHBristol.nhs.uk
Telefonas: +44 1173420815
Interneto adresas (-ai):
Pagrindinis adresas: https://www.nbt.nhs.uk/

I.4. Perkančiosios organizacijos tipas

Kitas tipas: NHS trust

I.5. Pagrindinė veikla

Sveikata

II dalis: Objektas

II.1. Pirkimo apimtis

II.1.1. Pavadinimas

Procurement of a Large Throughput DNA Sequencer
Nuorodos numeris: BWPCCL001501

II.1.2. Pagrindinis BVPŽ kodas

85111800 Patologijų gydymo paslaugos

II.1.3. Sutarties tipas

Paslaugos

II.1.4. Trumpas aprašymas

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per

run, providing flexibility across a broad range of applications and study sizes. The NovaSeq 6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Informacija apie pirkimo dalis

Ši sutartis suskaidyta į pirkimo dalis: ne

II.1.7. Bendra pirkimo vertė

Vertė be PVM: 779 625,00 GBP

II.2. Aprašymas

II.2.2. Kitas (-i) šio pirkimo BVPŽ kodas (-ai)

85111000 Ligoninių paslaugos

II.2.3. Įgyvendinimo vieta

NUTS kodas: UKK11 Bristol, City of

II.2.4. Pirkimo aprašymas

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a ‘universal’ gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Sutarties skyrimo kriterijai

Kokybės kriterijus - Vardas: Quality / Lyginamasis svoris: 90
Kaina - Lyginamasis svoris: 10

II.2.11. Informacija apie pasirinkimo galimybes

Pasirinkimo galimybės: ne

II.2.13. Informacija apie Europos Sąjungos fondus

Pirkimas yra susijęs su projektu ir (arba) programa, finansuojama Europos Sąjungos lėšomis: ne

II.2.14. Papildoma informacija

IV dalis: Procedūra

IV.1. Aprašymas

IV.1.1. Procedūros tipas

Sutarties skyrimas be išankstinio skelbimo apie kvietimą dalyvauti konkurse Europos Sąjungos oficialiajame leidinyje toliau išvardytais atvejais

- Pirkimui netaikoma direktyva

Paaiškinimas:
North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a ‘universal’ gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Informacija apie preliminariąją sutartį

IV.1.8. Informacija apie Sutartį dėl viešųjų pirkimų (SVP)

Ar pirkimui taikoma Sutartis dėl viešųjų pirkimų?: ne

IV.2. Administracinė informacija

V dalis: Sutarties skyrimas/koncesijos suteikimas

Pavadinimas:
Procurement of Large High Throughput DNA Sequencer

V.2. Sutarties skyrimas/koncesijos suteikimas

V.2.1. Sprendimo sudaryti sutartį priėmimo data
28/01/2020

V.2.2. Informacija apie pasiūlymus
Sutartis paskirta ekonominės veiklos vykdytojų grupei: ne

V.2.3. Rangovo arba koncesininko pavadinimas ir adresas
Oficialus pavadinimas: Illumina Cambridge Ltd
Adresas: Chesterford Research Park, Little Chesterford
Miestas: Saffron Walden
NUTS kodas: UKI London
Pašto kodas: CB10 1XL
Šalis: Jungtinė Karalystė
Būsimas rangovas arba koncesininkas yra MVĮ: taip

V.2.4. Informacija apie sutarties/pirkimo dalies/koncesijos vertę
Bendra sutarties / pirkimo dalies / koncesijos vertė: 779 625,00 GBP

V.2.5. Informacija apie subrangos sutarčių sudarymą

VI dalis: Papildoma informacija

VI.3. Papildoma informacija

VI.4. Peržiūros procedūros

VI.4.1. Peržiūros institucija
Oficialus pavadinimas: Bristol and Weston Purchasing Consortium
Adresas: Level 3, Whitefriars, Lewins Mead
Miestas: Bristol
Pašto kodas: BS1 2NT
Šalis: Jungtinė Karalystė
El. paštas: martin.strawson@UHBristol.nhs.uk

VI.4.2. Už tarpininkavimą atsakinga įstaiga
Oficialus pavadinimas: Bristol and Weston Purchasing Consortium
Adresas: Level 3, Whitefriars, Lewins Mead
Miestas: Bristol
Pašto kodas: BS1 2NT
Šalis: Jungtinė Karalystė

VI.4.4. Tarnyba, kuri gali suteikti informacijos apie peržiūros procedūrą
Oficialus pavadinimas: Bristol and Weston Purchasing Consortium
Adresas: Level 3, Whitefriars, Lewins Mead

Miestas: Bristol
Pašto kodas: BS1 2NT
Šalis: Jungtinė Karalystė

VI.5. Šio skelbimo išsiuntimo data

28/01/2020